Published on 5 Dec 2023 on Simply Wall St. via Yahoo Finance
After losing 39% in the past year, Denali Therapeutics Inc. (NASDAQ:DNLI) institutional owners must...
Key Insights
Given the large stake in the stock by institutions, Denali Therapeutics' stock price might be vulnerable to their trading decisionsThe top 10 shareholders own 50% of the companyUsing data from analyst forecasts alongside ownership research, one can better assess the future performance of a company
Every investor in Denali Therapeutics Inc. (NASDAQ:DNLI) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 79% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).